Current Issue : Anti-Cancer Drugs

Journal Logo

October 2023 - Volume 34 - Issue 9
pp: 971-1064

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models

El Shemerly, Mahmoud; Zanini, Elisa; Lecoultre, Marc; More

Anti-Cancer Drugs. 34(9):1035-1045, October 2023.